Ferric Carboxymaltose for Treatment of Anaemia of Cancer in Subjects With Multiple Myeloma Receiving Chemotherapy

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

October 31, 2011

Conditions
Iron-Deficiency Anemia
Interventions
DRUG

Ferric carboxymaltose

"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."

Trial Locations (2)

35203

Hopital Sud, Rennes

54007

Theagenion Cancer Center, Thessaloniki

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Vifor Pharma

INDUSTRY